Key facts
- This page summarizes Patrick Soon-Shiong's Form 4 filing for NantHealth, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 30 Aug 2023, 17:26.
Patrick Soon-Shiong - 28 Aug 2023 Form 4 Insider Report for NantHealth, Inc.
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 28 Aug 2023
- Net transaction value
- +$15,999,975
- SEC form
- 4
- Accepted by SEC
- 30 Aug 2023, 17:26:12 UTC
- Prior SEC filing
- 16 May 2023
- Next SEC filing
- 13 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Charles Kenworthy, Manager, Nant Capital, LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Soon-Shiong filed Form 4 for NantHealth, Inc. on 30 Aug 2023.
Change
- Previous filing in this sequence was filed on 16 May 2023.
- Current net transaction value: +$15,999,975.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NHIQ
transaction
Common Stock
Purchase
- Transaction value
- $6,000,000
- Shares
- +15,384,616
- Change %
- Price
- $0.3900
- Shares after
- 15,384,616
- Date
- 28 Aug 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2
NHIQ
transaction
Common Stock
Purchase
- Transaction value
- $9,999,975
- Shares
- +537,272
- Change %
- +3.5%
- Price
- $18.61*
- Shares after
- 15,921,888
- Date
- 28 Aug 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3
NHIQ
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,453,507
- Date
- 28 Aug 2023
- Ownership
- See Footnote
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Shares of common stock, par value $0.0001 per share ("Common Stock"), acquired from the issuer pursuant to a Stock Purchase Agreement (the "Purchase Agreement"), dated as of August 28, 2023, by and between the issuer and certain institutional and accredited investors, each as listed as signatories to the Purchase Agreement.
Footnote F2
Shares held by Nant Capital, LLC ("Nant Capital"). California Capital Equity, LLC ("CalCap") directly owns all of the equity interests of Nant Capital and CalCap may be deemed to have beneficial ownership of the shares held by Nant Capital. Patrick Soon-Shiong directly owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap.
Footnote F3
$10,000,000 aggregate principal amount of the demand promissory note, dated January 4, 2016, as amended and restated on May 9, 2016 and April 27, 2021, respectively, by and between the issuer and Nant Capital (the "Subordinated Nant Capital Promissory Note"), were exchanged for shares of Common Stock in accordance with the terms and conditions of the Subordinated Nant Capital Promissory Note.
Footnote F4
Includes (i) 4,147,469 shares of our common stock held by NantWorks, LLC; (ii) 193,426 shares of our common stock held by NantOmics, LLC; and (iii) 112,612 shares of our common stock held by Cambridge Equities, LP. NantWorks, LLC is the largest member of NantOmics, LLC, holding approximately 84% of the outstanding equity and approximately 99% of the outstanding voting equity. Dr. Patrick Soon-Shiong, is the controlling member of NantWorks, LLC with voting and dispositive power over the shares of the stock held by NantWorks, LLC. Dr. Patrick Soon-Shiong, indirectly owns all of the equity interests in NantWorks, LLC and Cambridge Equities, LP, and has voting and dispositive powers over the shares.
Footnote F5
On December 15, 2022, the issuer effected a 1-for-15 reverse stock split (the "Reverse Stock Split") of its outstanding shares of Common Stock. The numbers of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Split unless otherwise noted.